Dow Pharmaceutical Sciences, Inc.

Bausch Health Ireland Limited

Other

Valeant Pharmaceuticals North America

Bausch Health Us, LLC

Dermalogix Partners, Inc.

Gordon J Dow

Yunik Chang

Radhakrishnan Pillai

Arturo Angel

Varsha D Bhatt

David W Osborne

Pramod P Sarpotdar

Debra A Dow

Sarmistha Basu

Bhaskar Chaudhuri

Barry Calvarese

Kevin Bean

Robert W Lathrop

Daniel M Stewart

Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

Pharmaceutical formulations containing corticosteroids for topical administration

Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.

Topical compositions and methods for treating psoriasis

The present invention provides methods for treating onychomycosis. In certain embodiments, the methods comprise comprising applying a pharmaceutically acceptable formulation containing 10% efinaconazole once a day for a treatment period of at least 36 weeks to the treatment area of an onychomycosis patient (a) without debriding the nail or nail-associated tissue initially or during the treatment period and/or (b) without removing the formulation from the treatment area during the treatment period. In certain embodiments, the formulation also comprises, water, cyclomethicone, diisopropyl adipate, alcohol, C12-15 alkyl lactate, butylated hydroxytoluene, citric acid anhydrous, and disodium edetate.

Anti-infective methods, compositions, and devices

An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.

Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent

The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.

Topical pharmaceutical compositions comprise a combination of a corticosteroid and a retinoid; and methods for treating psoriasis with same. In one embodiment, the corticosteroid comprises halobetasol propionate, and the retinoid comprises tazarotene.

Growing community of inventors

Greenbrae, CA, United States of America

Gordon J Dow